Syndax CFO Executes Mixed Insider Transactions as Analysts Maintain Buy Ratings
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan completed a mix of share transactions in late January and early February 2026, including a sale of 2,082 shares for roughly $42,930, several zero-priced transfers, and an option award. The company also disclosed encouraging clinical results for its menin inhibitor Revuforj presented at …